COSMOS Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

COSMOS Pharmaceutical wird ein jährliches Gewinn- und Umsatzwachstum von 7.2% bzw. 7.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 7.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 11.1% betragen.

Wichtige Informationen

6.6%

Wachstumsrate der Gewinne

6.4%

EPS-Wachstumsrate

Consumer Retailing Gewinnwachstum	12.3%
Wachstumsrate der Einnahmen	6.6%
Zukünftige Eigenkapitalrendite	10.6%
Analystenabdeckung	Good
Zuletzt aktualisiert	26 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

COSMOS Pharmaceutical Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Apr 17

Recent updates

We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt

Sep 26

An Intrinsic Calculation For COSMOS Pharmaceutical Corporation (TSE:3349) Suggests It's 41% Undervalued

Aug 17

COSMOS Pharmaceutical (TSE:3349) Will Want To Turn Around Its Return Trends

Aug 01

Subdued Growth No Barrier To COSMOS Pharmaceutical Corporation's (TSE:3349) Price

Jun 28

We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt

Jun 10

COSMOS Pharmaceutical Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Apr 17

Some Shareholders Feeling Restless Over COSMOS Pharmaceutical Corporation's (TSE:3349) P/E Ratio

Mar 16

Returns On Capital At COSMOS Pharmaceutical (TSE:3349) Paint A Concerning Picture

Feb 28

Gewinn- und Umsatzwachstumsprognosen

TSE:3349 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (JPY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
5/31/2027	1,208,660	29,863	14,550	60,940	11
5/31/2026	1,126,266	27,794	4,966	57,228	12
5/31/2025	1,043,386	25,840	-1,718	49,801	13
5/31/2024	964,989	24,454	-635	55,175	N/A
2/29/2024	936,706	24,871	N/A	N/A	N/A
11/30/2023	900,111	24,085	681	54,534	N/A
8/31/2023	863,228	23,824	N/A	N/A	N/A
5/31/2023	827,697	23,797	7,798	54,434	N/A
2/28/2023	802,831	22,983	N/A	N/A	N/A
11/30/2022	788,292	23,209	-3,655	41,973	N/A
8/31/2022	772,127	23,393	N/A	N/A	N/A
5/31/2022	755,414	23,155	-11,303	32,194	N/A
2/28/2022	743,612	22,030	N/A	N/A	N/A
11/30/2021	733,387	25,329	-5	35,596	N/A
8/31/2021	726,672	25,909	N/A	N/A	N/A
5/31/2021	726,424	27,156	1,811	27,875	N/A
2/28/2021	733,223	28,777	N/A	N/A	N/A
11/30/2020	723,309	25,736	28,882	50,935	N/A
8/31/2020	709,064	23,876	N/A	N/A	N/A
5/31/2020	684,403	21,435	39,513	65,461	N/A
2/29/2020	653,527	20,217	N/A	N/A	N/A
11/30/2019	638,034	18,951	10,653	38,209	N/A
8/31/2019	622,103	19,349	N/A	N/A	N/A
5/31/2019	611,137	19,185	5,339	34,379	N/A
2/28/2019	597,715	18,966	N/A	N/A	N/A
11/30/2018	585,536	18,857	1,302	30,947	N/A
8/31/2018	572,807	17,880	N/A	N/A	N/A
5/31/2018	557,999	17,633	3,135	32,586	N/A
2/28/2018	542,936	17,510	N/A	N/A	N/A
11/30/2017	526,523	17,313	N/A	35,488	N/A
8/31/2017	514,880	18,239	N/A	N/A	N/A
5/31/2017	502,732	18,215	N/A	36,938	N/A
2/28/2017	490,037	15,812	N/A	N/A	N/A
11/30/2016	477,739	14,981	N/A	34,300	N/A
8/31/2016	463,517	13,679	N/A	N/A	N/A
5/31/2016	447,273	12,435	N/A	30,986	N/A
2/29/2016	433,328	12,738	N/A	N/A	N/A
11/30/2015	423,817	12,474	N/A	22,426	N/A
8/31/2015	414,046	12,350	N/A	N/A	N/A
5/31/2015	408,466	11,694	N/A	19,454	N/A
2/28/2015	402,690	10,671	N/A	N/A	N/A
11/30/2014	392,527	10,286	N/A	26,260	N/A
8/31/2014	382,823	10,193	N/A	N/A	N/A
5/31/2014	371,825	10,600	N/A	25,962	N/A
2/28/2014	360,162	10,366	N/A	N/A	N/A
11/30/2013	349,966	9,975	N/A	17,627	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 3349Das prognostizierte Gewinnwachstum (7.2% pro Jahr) liegt über der Sparquote (0.2%).

Ertrag vs. Markt: 3349Die Erträge des Unternehmens (7.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt JP (8.4% pro Jahr).

Hohe Wachstumserträge: 3349Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: 3349Die Einnahmen des Unternehmens (7.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt JP (3.9% pro Jahr).

Hohe Wachstumseinnahmen: 3349Die Einnahmen des Unternehmens (7.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 3349Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (11.1 %).

COSMOS Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

COSMOS Pharmaceutical Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending May 31, 2024

COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending May 31, 2024

COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending May 31, 2024

Cosmos Pharmaceutical Corporation Provides Earnings Forecast for the Fiscal Year Ending May 31, 2023

Price target decreased to JP¥14,800

Recent updates

We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt

Final dividend of JP¥32.50 announced

An Intrinsic Calculation For COSMOS Pharmaceutical Corporation (TSE:3349) Suggests It's 41% Undervalued

COSMOS Pharmaceutical Corporation to Report Q1, 2025 Results on Oct 11, 2024

COSMOS Pharmaceutical (TSE:3349) Will Want To Turn Around Its Return Trends

Full year 2024 earnings: EPS misses analyst expectations

COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 20, 2024

COSMOS Pharmaceutical Corporation Announces Year-End Dividend for the Fiscal Year Ended May 31, 2024, Payable on August 1, 2024; Provides Second Quarter End and Year End Dividend Guidance for the Fiscal Year Ending May 31, 2025

Subdued Growth No Barrier To COSMOS Pharmaceutical Corporation's (TSE:3349) Price

We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt

Upcoming dividend of JP¥60.00 per share

COSMOS Pharmaceutical Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Some Shareholders Feeling Restless Over COSMOS Pharmaceutical Corporation's (TSE:3349) P/E Ratio

Returns On Capital At COSMOS Pharmaceutical (TSE:3349) Paint A Concerning Picture

COSMOS Pharmaceutical Corporation to Report Q3, 2024 Results on Apr 12, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending May 31, 2024

Upcoming dividend of JP¥60.00 per share at 0.8% yield

COSMOS Pharmaceutical Corporation to Report Q2, 2024 Results on Jan 12, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending May 31, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

COSMOS Pharmaceutical Corporation to Report Q1, 2024 Results on Oct 11, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 22, 2023

COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending May 31, 2024

Upcoming dividend of JP¥42.50 per share at 0.6% yield

Third quarter 2023 earnings: EPS misses analyst expectations

COSMOS Pharmaceutical Corporation to Report Q3, 2023 Results on Apr 10, 2023

Second quarter 2023 earnings: EPS misses analyst expectations

Cosmos Pharmaceutical Corporation Provides Earnings Forecast for the Fiscal Year Ending May 31, 2023

Upcoming dividend of JP¥42.50 per share

No independent directors

COSMOS Pharmaceutical Corporation to Report Q2, 2023 Results on Jan 12, 2023

First quarter 2023 earnings: EPS exceeds analyst expectations

COSMOS Pharmaceutical Corporation Provides Dividend Guidance for the Second Quarter-End and Full Year of Fiscal Year Ending May 31, 2023

Full year 2022 earnings: EPS exceeds analyst expectations

COSMOS Pharmaceutical Corporation to Report Q1, 2023 Results on Oct 11, 2022

COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 23, 2022

Full year 2022 earnings: EPS exceeds analyst expectations

COSMOS Pharmaceutical Corporation Announces Dividend Guidance for the Second Quarter and Year End of Fiscal Year Ending May 31, 2023

Price target decreased to JP¥14,800

Upcoming dividend of JP¥40.00 per share

COSMOS Pharmaceutical Corporation to Report Fiscal Year 2022 Results on Jul 11, 2022

No independent directors

Third quarter 2022 earnings: EPS misses analyst expectations

COSMOS Pharmaceutical Corporation to Report Q3, 2022 Results on Apr 11, 2022

Second quarter 2022 earnings: EPS misses analyst expectations

Upcoming dividend of JP¥40.00 per share

First quarter 2022 earnings released: EPS JP¥158 (vs JP¥189 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥686 (vs JP¥541 in FY 2020)

Cosmos Pharmaceutical Corp to Be Deleted from Other OTC

Upcoming dividend of JP¥27.50 per share

Third quarter 2021 earnings released: EPS JP¥215 (vs JP¥138 in 3Q 2020)

Investor sentiment improved over the past week

COSMOS Pharmaceutical Corporation to Report Q3, 2021 Results on Apr 12, 2021

New 90-day low: JP¥15,820

Earnings beat expectations, revenue disappoints

Earnings beat expectations, revenue disappoints

Second quarter 2021 earnings released: EPS JP¥141

New 90-day low: JP¥16,110

New 90-day low: JP¥16,720

COSMOS Pharmaceutical Corporation to Report Q2, 2021 Results on Jan 12, 2021

COSMOS Pharmaceutical Corporation to Report Q1, 2021 Results on Oct 12, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite